Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 208-854-8 | CAS number: 543-94-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
A study on SrCl2, a structural analogue was used in a read-across approach. If the increased concentrations of strontium in the bone can be considered a non-toxic effect, a NOAEL of 300 ppm SrCl2 can be derived form this study which is based on the weight changes of thyroids at the doses of 1200 ppm (LOAEL) and 4800 ppm.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
- Remarks:
- Well-documented study. The study fulfils the requirements of the current test guideline for oral sub-chronic exposure to a great extent, but the study was not performed under GLP requirements.
- Justification for type of information:
- As few data are available on the target substance, a research of the potential analogues has been carried out.
The hypothesis is that properties are likely to be similar or follow a similar pattern as a result of the presence of a common metal ion (or ion complex including a hydrated metal ion). This is a reasonable assumption for the majority of inorganic compounds and some organic compounds (e.g. metal salts of some organic acids).
The following points are be considered:
- Chemical speciation and valency,
- The water solubility, as it provides a first indication of the availability of the metal ion in the different compartments of interest. The most simplistic approach to hazard evaluation is to assume that the specific metal-containing compound to be evaluated shows the same hazards as the most water-soluble compounds.
- Counter ions: the assumption that the metal ion is responsible for the common property or effect implies that the toxicity of the counter ion present in the compound will be largely irrelevant in producing the effects to be assessed.
Based on these data, we have selected the analogue Strontium chloride.
Strontium has also physiochemical properties similar to calcium and both appear mainly in ionic form in water.
A detail description is provided as attached report of this endpoint in this Iuclid file. - Reason / purpose for cross-reference:
- read-across source
- Other examinations:
- No
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- no effects observed
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- A lower leucocyte count noticed in the males of the 300 ppm group is not considered to be caused by the treatment, since at higher dose levels such an effect was not observed.
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- The glycogen concentration in the liver after 12 weeks showed a dose-related decrease, which was only significant in the females at the highest dose level.
Otherwise, analysis of alkaline phosphatase, SGPT (serum glutamine pyruvic acid transaminase) and urea in serum did not reveal any significant changes although in the highest dose group, an indication of an increased activity of Alk. Pase was noticed.
Microsomal liver enzyme activities did not show any changes.
The levels of Ca, Mg and P in the blood were not changed at any dose level, and the Ca/P ratio remained constant. The Ca, Mg and P concentrations in blood in all dose groups were higher after 8 weeks than after 12 weeks, which seems a physiological condition. - Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- not specified
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- - in males, relative thyroid weights were significantly increased in the 1200 and 4800 ppm groups
- in females, relative pituitary weights were significantly decreased in the 300 and 4800 ppm group, but not in the 1200 ppm group
- the relative prostate weights were significantely decreased at 75 and 1200 ppm (see Table III in attachment); this, however, must be considered with care, because proper preparation of the rat prostate is difficult - Gross pathological findings:
- no effects observed
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- - there were no changes seen on histopathological examination except slight changes in the liver and thyroid after blind examination (the changes consisted of a loss of glycogen in the liver at the highest dose level and a slightly increased activity in the thryroid of the males of the highest dose group)
- glycogen depletion may be caused by several factors other than strontium, such as stress , starvation or dirunal rhythm - Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- effects observed, treatment-related
- Description (incidence and severity):
- Detectable amounts of strontium chloride in blood and muscle were only noticed at the highest dose level whereas the strontium chloride concentration in bone was elevated at all dose levels.
- Details on results:
- CLINICAL SIGNS AND MORTALITY
- no relevant effects
- one control female died during bleeding procedure after more than 11 weeks
BODY WEIGHT AND WEIGHT GAIN
- no relevant effects
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study)
- food intake was not affected by exposure to strontium chloride hexahydrate
- no data on daily food intake are available in order to calculate daily dose levels
FOOD EFFICIENCY
- no relevant effects
HAEMATOLOGY
- the slightly elevated erythrocyte count noticed in the range-finding experiment was not confirmed in the 90-day study
- a lower leucocyte count noticed in the males of the 300 ppm group is not considered to be caused by the treatment, since at higher dose levels such an effect was not observed
CLINICAL CHEMISTRY
- Analysis of Alk. Pase, SGPT and urea in serum did not reveal any significant changes although in the highest dose group an indication of an increased activity of Alk. Pase was noticed. No clinical differences in clinical chemistry were noted except an indication of increased alkaline phosphatase activity in the highest dose group
- the levels of Ca, Mg and P in blood were similar for all dose levels and the Ca/P ratio was constant
- blood concentrations of Ca, Mg and P were higher at 8 weeks than 12 weeks, which seems a physiological condition
URINALYSIS
- urinalysis showed no differences in the groups
ORGAN WEIGHTS
- in males, relative thyroid weights were significantly increased in the 1200 and 4800 ppm groups
- in females, relative pituitary weights were significantly decreased in the 300 and 4800 ppm group, but not in the 1200 ppm group
- the relative prostate weights were significantely decreased at 75 and 1200 ppm (see Table III in attachment); this, however, must be considered with care, because proper preparation of the rat prostate is difficult
HISTOPATHOLOGY: NON-NEOPLASTIC
- there were no changes seen on histopathological examination except slight changes in the liver and thyroid after blind examination (the changes consisted of a loss of glycogen in the liver at the highest dose level and a slightly increased activity in the thryroid of the males of the highest dose group)
- glycogen depletion may be caused by several factors other than strontium, such as stress , starvation or dirunal rhythm
OTHER FINDINGS
- The glycogen concentration in the liver after 12 weeks showed a dose-related decrease, which was only significant in the female ath the highest dose level, which is may be caused by stress, starvation or diurnal rhythm
- microsomal liver enzyme activities did not show any changes
- detectable amounts of Sr in blood and muscle were only noticed at the dose of 4800 ppm
- the Sr content in bone was increased at all dose levels having a constant level from 4 weeks onwards (steady-state level)
- there were no changes seen in the X-ray photographs
- thus, up to the highest dose of 4800 ppm no rachitic changes occurred - Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 300 ppm
- Based on:
- test mat. (dissolved fraction)
- Sex:
- female
- Basis for effect level:
- organ weights and organ / body weight ratios
- Key result
- Dose descriptor:
- LOAEL
- Effect level:
- 1 200 ppm
- Sex:
- male
- Basis for effect level:
- organ weights and organ / body weight ratios
- Remarks on result:
- other: If the increased concentrations of strontium in the bone can be considered a non-toxic effect, a LOAEL of 1200 ppm SrCl2 can be derived from this study which is based on the weight changes of thyroids at the doses of 1200 ppm and 4800 ppm.
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 1 200 ppm
- System:
- endocrine system
- Organ:
- thyroid gland
- Treatment related:
- yes
- Dose response relationship:
- yes
- Relevant for humans:
- yes
- Conclusions:
- If the increased concentrations of strontium in the bone can be considered a non-toxic effect, a NOAEL of 300 ppm SrCl2 can be derived form this study which is based on the weight changes of thyroids at the doses of 1200 ppm (LOAEL) and 4800 ppm.
Reference
RANGE-FINDING EXPERIMENT
Behaviour, growth, food intake and food efficiency were not affected in the range-finding experiment. Haematological investigation revealed only a slight elevation of the total number of erythrocytes in males and females and a slight increase of the white cell count in the males at the highest dose level. No differences were found in liver and kidney weights and histopathological examination revealed no abnormalities. Sr in blood and muscle were only noted at the highest dose level whereas from 300 ppm onwards increased concentrations were found in bone.
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 100 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
Additional information
As few data are available on the target substance, a research of the potential analogues has been carried out.
The hypothesis is that properties are likely to be similar or follow a similar pattern as a result of the presence of a common metal ion (or ion complex including a hydrated metal ion). This is a reasonable assumption for the majority of inorganic compounds and some organic compounds (e.g. metal salts of some organic acids).
The following points are be considered:
- Chemical speciation and valency,
- The water solubility, as it provides a first indication of the availability of the metal ion in the different compartments of interest. The most simplistic approach to hazard evaluation is to assume that the specific metal-containing compound to be evaluated shows the same hazards as the most water-soluble compounds.
- Counter ions: the assumption that the metal ion is responsible for the common property or effect implies that the toxicity of the counter ion present in the compound will be largely irrelevant in producing the effects to be assessed.
Based on these data, we have selected strontium chloride as relevant analogue.
Strontium has also physiochemical properties similar to calcium and both appear mainly in ionic form in water.
In a sub-chronic feeding study by Kroes et al. (1977) SPF Wistar rats (40-60 g of body weight, 10 males and 10 females per group) received strontium chloride hexahydrate in a semi-purified diet at dose levels of 0, 75, 300, 1200, and 4800 ppm for 90 days. The diet contained adequate levels of Ca, Mg, P and vitamin D3. Growth, behaviour, food intake and food efficiency were not affected in the 90-day study.
No differences in clinical chemistry were noted, except of an indication of increased alkaline phosphatase activity in the highest dose group. Urinalysis showed no differences in the groups. The levels of Ca, Mg and P in blood were similar for all dose levels and the Ca/P ratio was constant.
In males, thyroid weights were significantly increased in the 1200 and 4800 ppm groups. Although, no clear explanation of this finding could be given it was regarded as treatement-related. In females, pituitary weights were significantly decreased in the 300 and 4800 ppm group, but not in the 1200 ppm group, and this finding was regarded as difficult to interpret. Glycogen depletion of the liver was noted in the highest dose group. However, this was may be caused by stress, stravation or diurnal rhythm and not by treatment with the test substance.
Detectable amounts of strontium in blood and muscle were only noticed at the dose of 4800 ppm. The strontium content in bone was increased at all dose levels having a constant level from 4 weeks onwards (steady-state level).
No treatment-related changes were observed in the X-ray photographs and on histopathological examination except, slight changes in the liver (glycogen depletion) and thyroid (activation). Thus, up to the highest dose of 4800 ppm no rachitic changes occurred.
Considering the increased concentrations of strontium in the bone as a non-toxic effect, a NOAEL of 300 ppm SrCl2 can be derived from this study based on the weight changes of thyroids at the doses of 1200 ppm (LOAEL) and 4800 ppm, and thyroid activation at 4800 ppm. No data on daily food intake are available in order to calculate daily dose levels. According to the estimation mentioned above, the NOAEL of 300 ppm strontium chloride (equal to 12.4 mg Sr/kg bw/d). This study is defined as key study.
Justification for classification or non-classification
The reference Kroes (1977) is considered as the key study for repeated dose toxicity via oral application and will be used for classification. Rats were dosed at 0, 75, 300, 1200, and 4800 ppm for 90 days. Since the increased concentrations of strontium in the bone can be considered a non-toxic effect, a NOAEL of 300 ppm SrCl2 can be derived from this study which is based on the weight changes of thyroids at the doses of 1200 ppm (LOAEL) and 4000 ppm. No data on daily food intake are available in order to calculate daily dose levels. According to the estimation mentioned above, the NOAEL of 300 ppm strontium chloride (equal to 12.4 mg Sr/kg bw/d).
The classification criteria according to regulation (EC) 1272/2008 as specific target organ toxicant (STOT) – repeated exposure, oral are not met, and thus no classification for specific target organ toxicant (STOT-RE) is required. However, some evidence of an effect of Sr on thyroid function is observed in the 90-day oral toxicity study in rats, but the incidence is very slight and seen only in males, but not in females, of the highest dose group tested, which is clearly above the cut-off levels for STOT-RE classification Cat2 (> 100 mg/kg bw/d rat oral, 90-day).
Hence, the NOAEL is considered at >100 mg/kg bw and no classification is needed.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.